Cretostimogene Monotherapy Elicits Durable CRs in High-Risk NMIBC onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
Dr Tyson on the Phase 3 BOND-003 Trial in BCG-Unresponsive NMIBC With CIS onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
IRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients
IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients